Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026

Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and…

Kyle LaHucik · 2026-08-31

Eli Lilly is further strengthening its position in immunology with its 13th acquisition of the year, paying up to $2.875 billion for Merida Biosciences and its asset in the increasingly popular subfields ...

Source: Endpoints News